Drug intelligence / Profile preview

recombinant canine VEGF analog

Development stage: Preclinical
Lead developer: Trophogen
Modality: Recombinant Proteins and Enzymes

Overview

Recombinant canine VEGF analog is a recombinant protein analog designed to interact with vascular endothelial growth factor (VEGF) receptors to modulate angiogenesis in veterinary indications. Developed by Trophogen, this therapeutic candidate mimics the activity of endogenous canine VEGF to stimulate or regulate the formation of new blood vessels. It is currently in preclinical development for various veterinary applications where angiogenic modulation is required.

Other names: canine VEGF analogrecombinant canine vascular endothelial growth factor analog

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR-1 (Vascular endothelial growth factor receptor 1)

Beyond the preview

Go deeper on recombinant canine VEGF analog.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant canine VEGF analog.

Explore the full profile